JP2014534202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014534202A5 JP2014534202A5 JP2014536116A JP2014536116A JP2014534202A5 JP 2014534202 A5 JP2014534202 A5 JP 2014534202A5 JP 2014536116 A JP2014536116 A JP 2014536116A JP 2014536116 A JP2014536116 A JP 2014536116A JP 2014534202 A5 JP2014534202 A5 JP 2014534202A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- peptide fragment
- amino acid
- acid residues
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims 37
- 108010033276 Peptide Fragments Proteins 0.000 claims 24
- 102000007079 Peptide Fragments Human genes 0.000 claims 24
- 125000000539 amino acid group Chemical group 0.000 claims 18
- 230000002163 immunogen Effects 0.000 claims 16
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 11
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 11
- 150000001413 amino acids Chemical class 0.000 claims 9
- 239000002671 adjuvant Substances 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108020000946 Bacterial DNA Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 102000043131 MHC class II family Human genes 0.000 claims 1
- 108091054438 MHC class II family Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 231100000588 tumorigenic Toxicity 0.000 claims 1
- 230000000381 tumorigenic effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170574 | 2011-10-17 | ||
| DKPA201170574 | 2011-10-17 | ||
| PCT/DK2012/050386 WO2013056716A1 (en) | 2011-10-17 | 2012-10-17 | Pd-l1 based immunotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014534202A JP2014534202A (ja) | 2014-12-18 |
| JP2014534202A5 true JP2014534202A5 (OSRAM) | 2015-12-03 |
| JP6259763B2 JP6259763B2 (ja) | 2018-01-10 |
Family
ID=47115103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014536116A Active JP6259763B2 (ja) | 2011-10-17 | 2012-10-17 | Ｐｄ−ｌ１に基づく免疫療法 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9669078B2 (OSRAM) |
| EP (2) | EP2768524B1 (OSRAM) |
| JP (1) | JP6259763B2 (OSRAM) |
| CN (2) | CN113444165A (OSRAM) |
| BR (1) | BR112014009526B8 (OSRAM) |
| CA (1) | CA2850245C (OSRAM) |
| CY (1) | CY1125453T1 (OSRAM) |
| DK (1) | DK2768524T3 (OSRAM) |
| ES (1) | ES2918580T3 (OSRAM) |
| HR (1) | HRP20220924T1 (OSRAM) |
| HU (1) | HUE059406T2 (OSRAM) |
| LT (1) | LT2768524T (OSRAM) |
| PL (1) | PL2768524T3 (OSRAM) |
| PT (1) | PT2768524T (OSRAM) |
| SI (1) | SI2768524T1 (OSRAM) |
| WO (1) | WO2013056716A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014009526B8 (pt) * | 2011-10-17 | 2023-01-17 | Herlev Hospital | Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer |
| US9637532B2 (en) * | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| US10816554B2 (en) | 2014-04-04 | 2020-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for T cell receptors |
| WO2016015095A1 (en) * | 2014-07-31 | 2016-02-04 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| WO2016041560A1 (en) | 2014-09-17 | 2016-03-24 | Herlev Hospital | Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof |
| JP6918333B2 (ja) * | 2014-09-17 | 2021-08-11 | 学校法人近畿大学 | 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤 |
| MX391478B (es) | 2014-10-10 | 2025-03-21 | Idera Pharmaceuticals Inc | Composiciones de agonista de tlr9 e inhibidores de punto de control para usarse en la respuesta inmune contra el cáncer. |
| WO2016077709A1 (en) * | 2014-11-14 | 2016-05-19 | Liquid Genomics, Inc. | Use of circulating cell-free rna for diagnosis and/or monitoring cancer |
| EP3294329B1 (en) * | 2015-05-15 | 2020-04-15 | Reber Genetics Co., Ltd. | Novel baculovirus vectors and methods of use |
| SG10202007937SA (en) * | 2015-09-02 | 2020-09-29 | Alnylam Pharmaceuticals Inc | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| CN108472345B (zh) | 2015-09-16 | 2023-05-23 | Io生物技术公司 | 包含c-c基序趋化因子22(ccl22)或其片段的疫苗组合物 |
| HUE064857T2 (hu) | 2016-03-04 | 2024-04-28 | Io Biotech Aps | Kombinációs terápia a rák ellen |
| AR108038A1 (es) * | 2016-03-14 | 2018-07-11 | Roche Innovation Ct Copenhagen As | Oligonucleótidos para reducir la expresión de pd-l1 (ligando de muerte programada-1) |
| CA3016474A1 (en) | 2016-03-15 | 2017-09-21 | Mersana Therapeutics, Inc. | Napi2b-targeted antibody-drug conjugates and methods of use thereof |
| CN109803674A (zh) | 2016-06-10 | 2019-05-24 | Io生物技术公司 | Calr和jak2疫苗组合物 |
| CN109641936B (zh) * | 2016-06-21 | 2023-11-28 | Io生物技术公司 | 用于癌症疫苗中的pdl1肽 |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| CN108503691B (zh) * | 2017-02-25 | 2021-07-23 | 复旦大学 | 一种人pd-l1蛋白高亲和性肽及其应用 |
| US20180271996A1 (en) | 2017-02-28 | 2018-09-27 | Mersana Therapeutics, Inc. | Combination therapies of her2-targeted antibody-drug conjugates |
| JP7247097B2 (ja) * | 2017-03-17 | 2023-03-28 | バクシム アクチェンゲゼルシャフト | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン |
| WO2019101954A1 (en) * | 2017-11-24 | 2019-05-31 | Io Biotech Aps | Enhancement of antibody-dependent cell-mediated cytotoxicity (adcc) |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| EP3727463A1 (en) | 2017-12-21 | 2020-10-28 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| FR3086534B1 (fr) * | 2018-10-01 | 2020-11-06 | Univ Bordeaux | Methode pour traiter une infection par le virus de l'immunodeficience humaine |
| AU2019369340A1 (en) | 2018-10-29 | 2021-05-20 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
| CN109593135B (zh) * | 2018-12-29 | 2021-01-15 | 百奥赛图江苏基因生物技术有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| WO2020181402A1 (zh) * | 2019-03-10 | 2020-09-17 | 胡西木 | 一种抗肿瘤多肽及其应用 |
| CN113249447A (zh) * | 2019-04-26 | 2021-08-13 | 嘉兴允英医学检验有限公司 | 一种pd-l1表达水平检测的方法和试剂盒 |
| JP7749543B2 (ja) * | 2019-09-17 | 2025-10-06 | オハイオ・ステイト・イノベーション・ファウンデーション | ヒト抗ｐｄ－ｌ１ペプチドワクチン及びその使用方法 |
| WO2021208106A1 (zh) * | 2020-04-18 | 2021-10-21 | 北京泽勤生物医药有限公司 | 一种治疗自身免疫病的融合肽 |
| CU24705B1 (es) * | 2020-10-22 | 2024-06-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| US20240245730A1 (en) * | 2021-05-17 | 2024-07-25 | Wisconsin Alumni Research Foundation | Synthetic protein for inducing immune tolerance |
| KR102421307B1 (ko) * | 2021-11-19 | 2022-07-14 | 을지대학교 산학협력단 | 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법 |
| US20250327041A1 (en) | 2022-02-24 | 2025-10-23 | Io Biotech Aps | Nucleotide delivery of cancer therapy |
| CN114702569B (zh) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | Pd-l1相关疫苗及其应用 |
| WO2025043075A1 (en) * | 2023-08-24 | 2025-02-27 | The Johns Hopkins University | Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury |
| EP4527849A1 (en) | 2023-09-19 | 2025-03-26 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Hla-independent antigen binders, such as t-cell receptors, against pd-l1 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| EP1230360A4 (en) * | 1999-11-09 | 2003-04-02 | Human Genome Sciences Inc | 15 HUMAN SECRETED PROTEINS |
| EP2388590A1 (en) * | 2001-04-02 | 2011-11-23 | Dana Farber Cancer Institute | PD-1, a receptor for B7-4, and uses thereof |
| WO2002086083A2 (en) * | 2001-04-20 | 2002-10-31 | Mayo Foundation For Medical Education And Research | Methods of enhancing cell responsiveness |
| AU2003281200A1 (en) * | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) * | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| WO2008085562A2 (en) * | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
| US20120269806A1 (en) | 2007-08-21 | 2012-10-25 | The General Hospital Corporation | Methods of inducing tolerance |
| CA2735006A1 (en) * | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Pd-1 antagonists and methods of use thereof |
| US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| IL300733B1 (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| BR112014009526B8 (pt) * | 2011-10-17 | 2023-01-17 | Herlev Hospital | Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer |
-
2012
- 2012-10-17 BR BR112014009526A patent/BR112014009526B8/pt active IP Right Grant
- 2012-10-17 EP EP12780408.6A patent/EP2768524B1/en active Active
- 2012-10-17 US US14/352,407 patent/US9669078B2/en active Active
- 2012-10-17 HR HRP20220924TT patent/HRP20220924T1/hr unknown
- 2012-10-17 CN CN202110437930.3A patent/CN113444165A/zh active Pending
- 2012-10-17 CA CA2850245A patent/CA2850245C/en active Active
- 2012-10-17 DK DK12780408.6T patent/DK2768524T3/da active
- 2012-10-17 SI SI201232003T patent/SI2768524T1/sl unknown
- 2012-10-17 PL PL12780408.6T patent/PL2768524T3/pl unknown
- 2012-10-17 WO PCT/DK2012/050386 patent/WO2013056716A1/en not_active Ceased
- 2012-10-17 CN CN201280050948.7A patent/CN103917243B/zh active Active
- 2012-10-17 LT LTEPPCT/DK2012/050386T patent/LT2768524T/lt unknown
- 2012-10-17 EP EP22163851.3A patent/EP4079319A1/en active Pending
- 2012-10-17 HU HUE12780408A patent/HUE059406T2/hu unknown
- 2012-10-17 JP JP2014536116A patent/JP6259763B2/ja active Active
- 2012-10-17 PT PT127804086T patent/PT2768524T/pt unknown
- 2012-10-17 ES ES12780408T patent/ES2918580T3/es active Active
-
2022
- 2022-08-02 CY CY20221100528T patent/CY1125453T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014534202A5 (OSRAM) | ||
| HRP20220924T1 (hr) | Imunoterapija zasnovana na pd-l1 | |
| JP2013507907A5 (OSRAM) | ||
| SI2280721T1 (en) | Indoleamine 2, 3-dioxygenase based immunotherapy | |
| JP2019506175A5 (OSRAM) | ||
| NZ616304A (en) | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses | |
| JP2014507146A5 (OSRAM) | ||
| JP2019030331A (ja) | 改良されたヒトヘルペスウイルス免疫療法用タンパク質 | |
| EA201591213A1 (ru) | Вакцины против вируса гепатита b | |
| RU2011138160A (ru) | Пептиды foxmi и вакцины, содержащие их | |
| JP2008530975A5 (OSRAM) | ||
| JP2016511221A5 (OSRAM) | ||
| JP2013545448A5 (OSRAM) | ||
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| JP2014139185A5 (OSRAM) | ||
| JP2014519311A5 (OSRAM) | ||
| RU2013158399A (ru) | Пептиды sema5b и содержащие их вакцины | |
| JP2013523084A5 (OSRAM) | ||
| RU2012147590A (ru) | Пептиды cdca5 и содержащие их вакцины | |
| RU2014140731A (ru) | Варианты гемагглютинина и нейраминидазы гриппа | |
| RU2014109137A (ru) | Пептиды mphosph1 и вакцины, включающие их | |
| JP2015529219A5 (OSRAM) | ||
| JP2012517239A5 (OSRAM) | ||
| JP2012526519A5 (OSRAM) | ||
| RU2011150283A (ru) | Пептиды ттк и вакцины, их содержащие |